Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Oncology
  • Oncology News
  • Chemotherapy more...

Chemotherapy more effective in relapsed ovarian cancer when coupled with cytoreductive surgery: NEJM

MD Editorial TeamWritten by MD Editorial Team Published On 2021-12-06T09:00:06+05:30  |  Updated On 6 Dec 2021 3:30 AM GMT
Chemotherapy more effective in relapsed ovarian cancer when coupled with cytoreductive surgery: NEJM
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • koo
  • Email

Delhi: A new study conducted by Philipp Harter and the team shows that cytoreductive surgery followed by chemotherapy resulted in longer overall survival in women with recurrent ovarian cancer than chemotherapy alone. The findings of this study were published in the New England Journal of Medicine on 14th November 2019.Systemic treatment has mostly been used to treat individuals with...

Delhi: A new study conducted by Philipp Harter and the team shows that cytoreductive surgery followed by chemotherapy resulted in longer overall survival in women with recurrent ovarian cancer than chemotherapy alone. The findings of this study were published in the New England Journal of Medicine on 14th November 2019.

Systemic treatment has mostly been used to treat individuals with recurrent ovarian cancer. The function of secondary cytoreductive surgery is unknown. As a result, the purpose of this trial was to see if subsequent cytoreduction would improve overall survival in women with platinum-sensitive, recurrent ovarian cancer who were otherwise surgical candidates.

This trial randomly allocated patients with recurrent ovarian cancer who had a first recurrence after a platinum-free interval of 6 months or more to have secondary cytoreductive surgery followed by platinum-based chemotherapy or to receive platinum-based chemotherapy alone. Patients were considered eligible if they had a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score, which was defined as an Eastern Cooperative Oncology Group performance-status score of 0 (on a 5-point scale, with higher scores indicating greater disability), ascites of fewer than 500 ml, and complete resection at initial surgery. A positive AGO score is used to identify individuals who may be candidates for full resection. Overall survival was the key end objective. Quality of life and survival predictive indicators were also evaluated.

A total of 407 patients were randomly randomized to one of two groups: 206 were assigned to cytoreductive surgery and chemotherapy, and 201 were assigned to chemotherapy alone. 75.5 percent of the patients in the surgical group who received the operation had a full resection. The median overall survival in the surgery group was 53.7 months and 46.0 months in the no-surgery group.

Patients who underwent a full resection had the best prognosis, with a median overall survival of 61.9 months. Surgery was found to be beneficial in all analyses and subgroups based on prognostic variables. Quality-of-life assessments were not different between the two groups after a year of follow-up, and there was no perioperative death within 30 days following surgery.

In conclusion, subsequent surgical cytoreduction in patients with platinum-sensitive, recurrent epithelial ovarian cancer who met these criteria looks possible, with tolerable postoperative morbidity, although it does not result in longer overall survival than no surgery.

Reference:

Philipp Harter, M.D., Ph.D., Jalid Sehouli, M.D., Ph.D., Ignace Vergote, M.D., Ph.D., Gwenael Ferron, M.D., Ph.D., et al.,Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. DOI: 10.1056/NEJMoa2103294

New England Journal of Medicineovarian cancercytoreductive surgerychemotherapy
Source : New England Journal of Medicine
MD Editorial Team
MD Editorial Team

    Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X